日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors

GFH018(一种转化生长因子-β受体I小分子抑制剂)在晚期实体瘤患者中的首次人体研究

Guo, Ye; Wang, Zishu; Zhou, Huan; Pan, Hongming; Han, Weidong; Deng, Yanhong; Li, Qun; Xue, Junli; Ge, Xiaoxiao; Wang, Shuang; Wang, Jing; Zhang, Yue; Zhao, Congqiao; Zhu, Huaqiang; Wang, Yu; Shen, Haige; Liu, Dong; Li, Jin

A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects.

一项 I 期随机、双盲、安慰剂对照研究,评估 RIPK1 抑制剂 GFH312 在健康受试者中的安全性和药代动力学

Lickliter Jason, Wang Shuang, Zhang Wenxin, Zhu Huaqiang, Wang Jing, Zhao Congqiao, Shen Haige, Wang Yu